Fulgent Genetics Inc’s Lock-Up Period To End on March 28th (NASDAQ:FLGT)
Fulgent Genetics’ (NASDAQ:FLGT) lock-up period is set to end on Tuesday, March 28th. Fulgent Genetics had issued 4,200,000 shares in its IPO on September 29th. The total size of the offering was $37,800,000 based on an initial share price of $9.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.
Separately, Zacks Investment Research upgraded shares of Fulgent Genetics from a “sell” rating to a “hold” rating in a research report on Thursday, March 16th.
Your IP Address:
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/fulgent-genetics-incs-lock-up-period-to-end-on-march-28th-nasdaqflgt.html
Fulgent Genetics (NASDAQ:FLGT) opened at 11.29 on Tuesday. The firm’s 50-day moving average is $11.53 and its 200 day moving average is $10.56. The company’s market cap is $199.56 million. Fulgent Genetics has a 52-week low of $7.59 and a 52-week high of $13.90.
Institutional investors have recently bought and sold shares of the company. Putnam Investments LLC raised its position in Fulgent Genetics by 1.2% in the fourth quarter. Putnam Investments LLC now owns 374,700 shares of the company’s stock valued at $4,335,000 after buying an additional 4,400 shares during the period. Baker BROS. Advisors LP purchased a new position in Fulgent Genetics during the third quarter valued at $1,153,000. Laurion Capital Management LP purchased a new position in Fulgent Genetics during the third quarter valued at $277,000. Finally, Monashee Investment Management LLC purchased a new position in Fulgent Genetics during the third quarter valued at $2,584,000. 13.40% of the stock is owned by institutional investors.
Fulgent Genetics Company Profile
Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.
Receive News & Ratings for Fulgent Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.